Lewy body co‐pathology in Alzheimer’s disease and primary age‐related tauopathy contributes to differential neuropathological, cognitive, and brain atrophy patterns

by | Monday, December 23, 2024 | Dementia

Abstract INTRODUCTION Alzheimer’s disease (AD) co-pathology with Lewy bodies (LB) is frequent and influences clinical manifestations and outcomes. Its significance in primary age-related tauopathy (PART) is unknown. We investigated the influence of LB on...

ADNI Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion (DE&I) Working Group: A new collaboration that crosses boundaries for industry, academia, and under‐represented patients

by | Monday, December 23, 2024 | Dementia

Abstract The Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion Working Group (DE&I WG) was established to work with the ADNI3 Diversity Task Force to provide an industry perspective...

Alzheimer’s disease‐associated CD83(+) microglia are linked with increased immunoglobulin G4 and human cytomegalovirus in the gut, vagal nerve, and brain

by | Thursday, December 19, 2024 | Dementia

Abstract INTRODUCTION While there may be microbial contributions to Alzheimer’s disease (AD), findings have been inconclusive. We recently reported an AD-associated CD83(+) microglia subtype associated with increased immunoglobulin G4 (IgG4) in the transverse...